GSK547A

GSK547A is a highly selective small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) activity, developed by GSK. RIPK1 is a key mediator of pro-inflammatory cytokine production and necroptotic cell death, processes that are implicated in the pathogenesis of various inflammatory diseases, including inflammatory bowel disease (IBD). In preclinical studies, specifically using the mouse T-cell transfer model of colitis, GSK547A demonstrated significant anti-inflammatory potential by reducing mucosal damage, decreasing colon density, and lowering the expression of pro-inflammatory cytokines such as TNF-α, IL-17A, INF-γ, IL-6, and MCP-1. These findings support the ongoing clinical evaluation of RIPK1 kinase inhibition as a therapeutic strategy for patients with ulcerative colitis and Crohn's disease.